Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27796854 | 0.87 | HPGD (0.47) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL6691919 | 0.85 | NOTUM (0.60) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL9800935 | 0.85 | HPGD (0.46) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL12919995 | 0.82 | ALDH1A1 (0.54) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL13309261 | 0.82 | HTR2A (0.45) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL25014859 | 0.82 | MEN1 (0.54) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL20897098 | 0.82 | RAB9A (0.47) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL13309263 | 0.82 | RAB9A (0.45) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL19193156 | 0.79 | ALDH1A1 (0.43) | HPGDNOTUMRAB9ANPC1ALDH1A1 | |
| SCHEMBL28208186 | 0.78 | ALDH1A1 (0.46) | HPGDNOTUMRAB9AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1757585-B1 | Anionically substituted 7-Nitroindoline derivatives and their uses | MEDICAL RES COUNCIL (GB) | 2010-12-01 | — | — | EP | disclosed |
| US-7737169-B2 | Anionically substituted 7-nitroindoline derivatives and their uses | MEDICAL RESEARCH COUNCIL (GB) | 2010-06-15 | — | — | US | disclosed |
| US-7737169-B2 | Anionically substituted 7-nitroindoline derivatives and their uses | MEDICAL RESEARCH COUNCIL (GB) | 2010-06-15 | — | — | US | disclosed |
| EP-1377548-B1 | PROCESS FOR NITRATING PHOTOCLEAVABLE COMPOUNDS | MEDICAL RES COUNCIL (GB) | 2009-02-18 | — | — | EP | disclosed |
| US-20070203099-A1 | Anionically substituted 7-nitroindoline derivatives and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2007-08-30 | — | — | US | disclosed |
| US-20070203099-A1 | Anionically substituted 7-nitroindoline derivatives and their uses | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2007-08-30 | — | — | US | disclosed |
| EP-1757585-A1 | Anionically substituted 7-Nitroindoline derivatives and their uses | Medical Research Council (GB) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203099-A1 | Anionically substituted 7-nitroindoline derivatives and their uses | SLC18A3, SLC18A1, SLC18A2 | HPGD 265/4885NOTUM 4240/4885RAB9A 550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.